Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsThe development of advanced biotherapeutics is frequently constrained by glycosylation-related challenges, including immunogenicity risks, inconsistent product quality, and suboptimal pharmacokinetics. Creative Biolabs' Biosafety Optimization & Glyco Simplification Services directly address these obstacles. We employ a strategic integration of precision techniques, such as chemo-enzymatic remodeling, CRISPR-based engineering, and metabolic pathway modulation, to actively redesign glycan profiles. This enables the creation of superior "bio-better" candidates with enhanced safety, controlled functionality, and improved developability, ultimately elevating the therapeutic index and de-risking your clinical translation path.
The glycosylation profile of a biologic is a decisive factor for its clinical success, directly governing immunogenic risk, pharmacokinetic behavior, and functional potency. Suboptimal glycan structures are documented to precipitate rapid clearance and adverse immune responses. At Creative Biolabs, we advance beyond analytical characterization through our Rational Glyco-Design platform. By integrating precise genetic and enzymatic remodeling technologies, we actively engineer optimal glycosylation to transform lead candidates into safer, more potent, and developable "bio-better" therapeutics.
Fig.1 Glycan engineering for therapeutic safety and precision.
Creative Biolabs offers comprehensive services to refine complex biologic candidates into safe, efficacious, and development-ready therapeutics. We demystify glycosylation by streamlining glycan profiles to enhance safety and by enriching key glycoforms to potentiate critical effector mechanisms such as antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
Our Biosafety Optimization & Glyco Simplification Services offer two strategic paths to refine antibody properties. We provide dedicated platforms to either maximize clinical safety through humanized glycosylation or to engineer precise functional profiles via glycan simplification, directly addressing critical development challenges.
This service focuses on eliminating immunogenic non-human glycan epitopes, such as α-Gal and Neu5Gc, by engineering production cell lines to synthesize fully human glycosylation profiles. The resulting antibodies exhibit maximum biocompatibility, significantly reducing the risk of immunogenicity and adverse immune responses in patients. It is particularly critical for therapeutics intended for chronic administration or in patient populations with pre-existing anti-glycan antibodies, ensuring superior long-term safety and clinical acceptability.
Learn More →Designed for applications requiring attenuated Fc-mediated effector functions or enhanced molecular homogeneity, this service provides tailored glycosylation simplification. Through precise genetic or enzymatic approaches, glycosylation sites can be eliminated, or glycans systematically reduced to a core structure. This optimization is invaluable for antibody formats where effector activation is undesirable, such as certain targeting modalities, or where batch-to-batch consistency and simplified analytical characterization are paramount for development and regulatory approval.
Learn More →Required Starting Materials: To commence the project, the following materials are typically required: the amino acid sequence of the target antibody or protein, details of the current expression system, and any existing glycomics profiling data, such as preliminary mass spectrometry reports, from prior experimental runs.
Key Steps:
Final Deliverables: Upon project completion, you will receive a detailed Glycan Characterization Report quantifying all glycoforms, a formal Safety Assessment Dossier verifying the elimination of immunogenic epitopes, and the final optimized, purified biologic material in the requested scale.
Partner with us for a strategic alliance grounded in profound glycobiology proficiency. We provide more than analytical results—we deliver actionable insights that convert intricate glycosylation patterns into definitive improvements in therapeutic safety and potency. Our validated platforms streamline development timelines and mitigate project risks, guaranteeing your biologic is precision-engineered for both clinical impact and market success.
"Implementing their enzymatic glycan refinement platform was transformative for our ADC program, enabling a shift from variable drug-loading to a precisely defined average DAR. This level of control was critical for our successful regulatory submission." Dr. Al***on S.
"Their rapid metabolic engineering solution enabled the production of afucosylated antibodies using our established CHO platform, bypassing the lengthy process of generating a novel knockout cell line. The resulting ADCC enhancement aligned perfectly with projected models." Mark v** d** B***.
"The targeted removal of non-human sialic acid residues from our candidate was essential for advancing into high-dose clinical phases. Their expertise in glycobiology risk mitigation is a definitive industry benchmark." Prof. Li*** W*.
We operate a specialized Antibody Glyco Optimization Platform. To jointly enhance the safety and efficacy of your biologics using our advanced technological capabilities, we cordially invite you to participate in an exploratory call. Our dedicated team of glycobiology experts is ready to engage in a detailed discussion of your specific project objectives and to develop a tailored optimization strategy for your needs.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
